{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,3]],"date-time":"2026-02-03T03:26:52Z","timestamp":1770089212215,"version":"3.49.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T00:00:00Z","timestamp":1767398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":30,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Beum Saeng Kim academic research fund, Department of Neurology, The Catholic University of Korea"},{"name":"the Hanmi pharm. Co."},{"name":"The Uijeongbu St. Mary\u2019s Hospital Clinical Research Laboratory Foundation made in the program of 2022"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Alz Res Therapy"],"DOI":"10.1186\/s13195-025-01942-0","type":"journal-article","created":{"date-parts":[[2026,1,4]],"date-time":"2026-01-04T02:16:12Z","timestamp":1767492972000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of dose and compliance of antidementia medications on long-term outcomes in Alzheimer\u2019s disease: a nationwide real-world study"],"prefix":"10.1186","volume":"18","author":[{"given":"Taewon","family":"Kim","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun Jeong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoonjong","family":"Bae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Si Baek","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seong Hoon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myung Ah","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eunbuel","family":"Ko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeong Wook","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong Won","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,3]]},"reference":[{"key":"1942_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.12779\/dnd.2025.24.1.1","volume":"24","author":"Y Kim","year":"2025","unstructured":"Kim Y, Kang DW, Kim GH, Kim KW, Kim HJ, Na S, et al. Clinical practice guidelines for dementia: recommendations for cholinesterase inhibitors and memantine. Dement Neurocogn Disord. 2025;24:1\u201323.","journal-title":"Dement Neurocogn Disord"},{"key":"1942_CR2","first-page":"1590","volume":"49","author":"PN Tariot","year":"2001","unstructured":"Tariot PN, Cummings JL, Katz IR, Mintzer J, Perdomo CA, Schwam EM, et al. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with alzheimer\u2019s disease in the nursing home setting. J Am Geriatr Soc. 2001;49:1590\u20139.","journal-title":"J Am Geriatr Soc"},{"key":"1942_CR3","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1212\/WNL.57.3.489","volume":"57","author":"B Winblad","year":"2001","unstructured":"Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A, et al. <article-title update=\"added\">A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology. 2001;57:489\u201395.","journal-title":"Neurology"},{"key":"1942_CR4","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1001\/archneur.61.12.1852","volume":"61","author":"B Seltzer","year":"2004","unstructured":"Seltzer B, Zolnouni P, Nunez M, Goldman R, Kumar D, Ieni J, et al. Efficacy of donepezil in early-stage alzheimer disease: a randomized placebo-controlled trial. Arch Neurol. 2004;61:1852\u20136.","journal-title":"Arch Neurol"},{"key":"1942_CR5","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1136\/bmj.321.7274.1445","volume":"321","author":"GK Wilcock","year":"2000","unstructured":"Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate alzheimer\u2019s disease: multicentre randomised controlled trial. BMJ. 2000;321:1445\u20139.","journal-title":"BMJ"},{"key":"1942_CR6","doi-asserted-by":"publisher","first-page":"852","DOI":"10.1002\/gps.409","volume":"16","author":"D Wilkinson","year":"2001","unstructured":"Wilkinson D, Murray J. Galantamine: a randomized, double-blind, dose comparison in patients with alzheimer\u2019s disease. Int J Geriatr Psychiatry. 2001;16:852\u20137.","journal-title":"Int J Geriatr Psychiatry"},{"key":"1942_CR7","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1001\/jama.291.3.317","volume":"291","author":"PN Tariot","year":"2004","unstructured":"Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317\u201324.","journal-title":"JAMA"},{"key":"1942_CR8","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1212\/01.WNL.0000129990.32253.7B","volume":"63","author":"C Holmes","year":"2004","unstructured":"Holmes C, Wilkinson D, Dean C, Vethanayagam S, Olivieri S, Langley A, et al. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in alzheimer disease. Neurology. 2004;63:214\u20139.","journal-title":"Neurology"},{"key":"1942_CR9","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1016\/S0140-6736(04)16499-4","volume":"363","author":"C Courtney","year":"2004","unstructured":"Courtney C, Farrell D, Gray R, Hills R, Lynch L, Sellwood E, et al. Long-term donepezil treatment in 565 patients with alzheimer\u2019s disease (AD2000): randomised double-blind trial. Lancet. 2004;363:2105\u201315.","journal-title":"Lancet"},{"key":"1942_CR10","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1046\/j.1365-2389.2003.51306.x","volume":"51","author":"DS Geldmacher","year":"2003","unstructured":"Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR. Donepezil is associated with delayed nursing home placement in patients with Alzheimer\u2019s disease. J Am Geriatr Soc. 2003;51:937\u201344.","journal-title":"J Am Geriatr Soc"},{"key":"1942_CR11","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1136\/jnnp.2008.158964","volume":"80","author":"OL Lopez","year":"2009","unstructured":"Lopez OL, Becker JT, Wahed AS, et al. Long-term effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80:600\u20137.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"1942_CR12","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/j.jalz.2012.09.015","volume":"9","author":"CW Zhu","year":"2013","unstructured":"Zhu CW, Livote EE, Scarmeas N, Albert M, Brandt J, Blacker D, et al. Long-term associations between cholinesterase inhibitors and memantine use and health outcomes among patients with alzheimer\u2019s disease. Alzheimers Dement. 2013;9:733\u201340.","journal-title":"Alzheimers Dement"},{"key":"1942_CR13","doi-asserted-by":"publisher","first-page":"4451","DOI":"10.1038\/s41598-022-08595-1","volume":"12","author":"J Byun","year":"2022","unstructured":"Byun J, Lee DY, Jeong CW, Kim Y, Rhee HY, Moon KW, et al. Analysis of treatment pattern of anti-dementia medications in newly diagnosed Alzheimer\u2019s dementia using OMOP CDM. Sci Rep. 2022;12:4451.","journal-title":"Sci Rep"},{"key":"1942_CR14","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.archger.2007.08.012","volume":"47","author":"C Han","year":"2008","unstructured":"Han C, Jo SA, Jo I, Kim E, Park MH, Kang Y. An adaptation of the Korean mini-mental state examination (K-MMSE) in elderly koreans: demographic influence and population-based norms (the AGE study). Arch Gerontol Geriatr. 2008;47:302\u201310.","journal-title":"Arch Gerontol Geriatr"},{"key":"1942_CR15","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1212\/WNL.43.11.2412-a","volume":"43","author":"JC Morris","year":"1993","unstructured":"Morris JC. The clinical dementia rating (CDR): current version and scoring rules. Neurology. 1993;43:2412\u20134.","journal-title":"Neurology"},{"key":"1942_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/alzrt7","volume":"1","author":"SD Rountree","year":"2009","unstructured":"Rountree SD, Chan W, Pavlik VN, et al. Persistent treatment with cholinesterase inhibitors and\/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1:7.","journal-title":"Alzheimers Res Ther"},{"key":"1942_CR17","doi-asserted-by":"publisher","first-page":"e2220","DOI":"10.1212\/WNL.0000000000011832","volume":"96","author":"H Xu","year":"2021","unstructured":"Xu H, Garcia-Ptacek S, J\u00f6nsson L, Wimo A, Nordstr\u00f6m P, Eriksdotter M. Long-term effects of cholinesterase inhibitors on cognitive decline and mortality. Neurology. 2021;96:e2220\u201330.","journal-title":"Neurology"},{"key":"1942_CR18","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.trci.2019.05.005","volume":"5","author":"S Bhattacharjee","year":"2019","unstructured":"Bhattacharjee S, Patanwala AE, Lo-Ciganic WH, Malone DC, Lee JK, Knapp SM, et al. Alzheimer\u2019s disease medication and risk of all-cause mortality and all-cause hospitalization: a retrospective cohort study. Alzheimers Dement (N Y). 2019;5:294\u2013302.","journal-title":"Alzheimers Dement (N Y)"},{"key":"1942_CR19","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1471-2377-14-83","volume":"14","author":"K Meguro","year":"2014","unstructured":"Meguro K, Kasai M, Akanuma K, Meguro M, Ishii H, Yamaguchi S. Donepezil and life expectancy in Alzheimer\u2019s disease: a retrospective analysis in the Tajiri project. BMC Neurol. 2014;14:83.","journal-title":"BMC Neurol"},{"key":"1942_CR20","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1159\/000437050","volume":"40","author":"C Wattmo","year":"2015","unstructured":"Wattmo C, Londos E, Minthon L. Longitudinal associations between survival in Alzheimer\u2019s disease and cholinesterase inhibitor use, progression, and community based services. Dement Geriatr Cogn Disord. 2015;40:297\u2013310.","journal-title":"Dement Geriatr Cogn Disord"},{"key":"1942_CR21","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1093\/eurheartj\/eht182","volume":"34","author":"P Nordstrom","year":"2013","unstructured":"Nordstrom P, Religa D, Wimo A, Winblad B, Eriksdotter M. The use of cholinesterase inhibitors and the risk of myocardial infarction and death: a nationwide cohort study in subjects with Alzheimer\u2019s disease. Eur Heart J. 2013;34:2585\u201391.","journal-title":"Eur Heart J"}],"container-title":["Alzheimer's Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13195-025-01942-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13195-025-01942-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T14:36:26Z","timestamp":1770042986000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13195-025-01942-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,3]]},"references-count":21,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1942"],"URL":"https:\/\/doi.org\/10.1186\/s13195-025-01942-0","relation":{},"ISSN":["1758-9193"],"issn-type":[{"value":"1758-9193","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,3]]},"assertion":[{"value":"9 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Review Board (UC23ZASI0016). The study was conducted in accordance with the Declaration of Helsinki and principles of Good Clinical Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}],"article-number":"24"}}